Hyperglycemia in extremely- low-birth-weight infants

Area of Science:

• Neonatalogy
• Endocrinology
• Metabolic Disorders

Background:

• Hyperglycemia is a common issue in extremely-low-birth-weight (ELBW) infants, but its causes are not fully understood.
• Insulin-like growth factors (IGF-I and IGF-II) are crucial for infant growth, and their potential role in ELBW infant hyperglycemia warrants investigation.

Purpose of the Study:

• To investigate the relationship between hyperglycemia and serum levels of IGF-I and IGF-II in ELBW infants.
• To compare the efficacy and safety of continuous insulin infusion versus glucose intake reduction for managing hyperglycemia in ELBW infants.

Main Methods:

• A cohort of 56 ELBW infants (<1,000 g) were studied.
• Infants developing hyperglycemia were randomized to receive either reduced glucose intake or continuous insulin infusion.
• Control group (n=33) maintained normal blood glucose levels. Blood samples were collected on days 3, 8, and 15, and upon hyperglycemia development.

Main Results:

• Hyperglycemic infants had lower birth weights than controls.
• No significant differences in baseline IGF-I or IGF-II levels were found between hyperglycemic and control infants.
• Insulin infusion was safe and maintained caloric intake, while glucose reduction led to prolonged caloric deprivation.

Conclusions:

• IGF-I and IGF-II are not associated with hyperglycemia in ELBW infants.
• ELBW infants with hyperglycemia do not typically present with baseline insulin deficiency and often show a normal insulin response.
• Continuous insulin infusion is a safe and effective method for managing hyperglycemia in ELBW infants, ensuring adequate nutrition.